

Bio: Alex Karanevich finished his PhD in Biostatistics at the University of Kansas Medical Center in 2017, where he focused on applying Bayesian methodology to amyotrophic lateral sclerosis (ALS) data. He then entered the pharmaceutical industry by way of EMB Statistical Solutions, a CRO specializing in statistical programming and analysis. As a now Senior Biostatistician, Alex has worked and consulted in the design and analysis of many clinical trials, ranging from early phase I to post-marketing phase IV. These trials have included a wide variety of disease indications, with a continued focus on ALS research.